$ Value
—
Shares
22,481
Price
—
Filed
Jul 8
Insider
Name
Savitz Adam
Title
CHIEF MEDICAL OFFICER
CIK
0002008707
Roles
Transaction Details
Transaction Date
2025-07-03
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
22,481
Footnotes
The shares subject to the option are fully vested and exercisable. | The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. | Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. | 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. | 25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. | 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. | 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Filing Info
Savitz Adam's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-11 | ANRO | A | $0 |
| 2025-07-03 | ANRO | A | — |
| 2025-07-03 | ANRO | D | — |
| 2025-07-03 | ANRO | A | — |
| 2025-07-03 | ANRO | D | — |
| 2025-07-03 | ANRO | A | — |
| 2025-07-03 | ANRO | D | — |
| 2025-07-03 | ANRO | A | — |
| 2025-07-03 | ANRO | D | — |
| 2025-07-03 | ANRO | A | — |
Other Insiders at ANRO (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Hanley Jr. Michael Conick
CHIEF OPERATING OFFICER
|
— | — | 2026-02-11 |
|
Etkin Amit
PRESIDENT AND CEO
|
— | — | 2026-03-01 |
|
Savitz Adam
CHIEF MEDICAL OFFICER
|
— | — | 2026-02-11 |
|
Smith Nicholas Conrad
CHIEF FINANCIAL OFFICER & CBO
|
— | — | 2026-03-01 |